长链非编码RNA ZNF667-AS1在非小细胞肺癌组织中表达上调

梁海梅.长链非编码RNA ZNF667-AS1在非小细胞肺癌组织中表达上调[J].内科急危重症杂志,2022,28(4):305-307

扫码阅读全文

DOI：10.11768/nkjwzzzz20220411

英文关键词:

基金项目:海南省自然科学基金资助（No：818MS136）

作者	单位	E-mail
梁海梅	中南大学湘雅医学院附属海口医院	lianghaimeit88@163.com

摘要点击次数: 1141

全文下载次数: 1627

中文摘要:

目的:探讨非小细胞肺癌（NSCLC）组织中长链非编码RNA（lncRNA）锌指蛋白667反义RNA1（ZNF667-AS1）的表达水平。方法： 97例NSCLC患者被纳入本研究，术中留取新鲜的癌组织及对应癌旁组织，采用实时定量聚合酶链式反应（PCR）法检测lncRNA ZNF667-AS1和血管内皮生长因子（VEGF）的表达，分析lncRNA ZNF667-AS1的表达与NSCLC患者临床病理特征的关系，绘制受试者工作特征（ROC）曲线，评估lncRNA ZNF667-AS1用于诊断NSCLC的价值，分析癌组织中VEGF的表达与lncRNA ZNF667-AS1表达的相关性。结果：PCR检测结果显示，97例NSCLC患者癌组织中lncRNA ZNF667-AS1的平均相对表达量明显高于癌旁组织（P<0.05）。不同性别、年龄、肿瘤直径及病理组织类型的NSCLC患者癌组织中lncRNA ZNF667-AS1相对表达量比较，差异无统计学意义（P均＞0.05），但不同组织分化程度、临床分期、浸润程度及有无淋巴结转移的患者癌组织中lncRNA ZNF667-AS1相对表达量比较，差异有统计学意义（P均<0.05）。实时荧光定量PCR检测结果显示，NSCLC癌组织中VEGF的相对表达量明显高于癌旁组织（P<0.01），NSCLC癌组织中lncRNA ZNF667-AS1的相对表达量与VEGF的表达呈正相关（P<0.05）。由ROC曲线可知，lncRNA ZNF667-AS1诊断NSCLC的AUC为0.792（95%CI：0.683-0.911，P﹤0.05），特异性为81.23%，敏感度为86.12%。结论： lncRNA ZNF667-AS1在NSCLC组织中表达上调，其可能作为一种促癌因子参与NSCLC的发生发展过程。

英文摘要:

Objective: To investigate the expression level of long non-coding RNA (lncRNA) zinc finger protein 667 antisense RNA1 (ZNF667-AS1) in non-small cell lung cancer tissues. Methods: A total of 97 patients with NSCLC were included in this study. Fresh cancer tissues and corresponding paracancerous tissues were collected during surgery, and real-time quantitative polymerase chain reaction (PCR) was used to detect lncRNA ZNF667-AS1 and vascular endothelial growth factor (VEGF). The relationship between the expression of lncRNA ZNF667-AS1 and the clinicopathological characteristics of NSCLC patients was analyzed. The receiver operating characteristic (ROC) curve was drawn, and the value of lncRNA ZNF667-AS1 in the diagnosis of NSCL was evaluated. Correlation between lncRNA ZNF667-AS1 expression and VEGF expression in lung cancer tissues was analyzed. Results: The PCR results showed that the average relative expression of lncRNA ZNF667-AS1 in cancer tissues of 97 NSCLC patients was significantly higher than that in adjacent tissues (P<0.05). There was no significant difference in the relative expression of lncRNA ZNF667-AS1 in cancer tissues of NSCLC patients with different genders, ages, tumor diameters and pathological tissue types (all P>0.05). The relative expression of lncRNA ZNF667-AS1 in cancer tissues of patients with or without lymph node metastasis showed statistically significant difference (P<0.05). The results of real-time fluorescence quantitative PCR showed that the relative expression of VEGF in NSCLC cancer tissues was significantly higher than that in adjacent tissues (P<0.01), and the relative expression of lncRNA ZNF667-AS1 in NSCLC cancer tissues was positively correlated with the expression of VEGF (P<0.01). The area under the ROC curve (AUC) of lncRNA ZNF667-AS1 in the diagnosis of NSCLC was 0.792 (95% CI: 0.683-0.911, P<0.05), the specificity was 81.23%, and the sensitivity was 86.12%. Conclusion: The expression of lncRNA ZNF667-AS1 is up-regulated in NSCLC tissues, and it may be involved in the occurrence and development of NSCLC as a tumor-promoting factor.